A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy 2015:submit your manuscript | www.dovepress.comDovepressGraveel et alDovepressTable 2 (Continued)Gene locus MIR423 SNP rs6505162 A/C Comments premiRNA Population Caucasian Jewish BRCA2 carriers Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans Chinese Asians Caucasians Asians Caucasians Chinese Caucasians Asians Caucasians Asians Caucasians Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Jewish BRCA2 carriers Caucasian italian Chinese Jewish BRCA1 carriers Chinese Clinical observation Lowered risk Later age of onset No risk Daporinad association No risk association No risk association Decreased Fingolimod (hydrochloride) chemical information danger of eR+ BC No threat association increased overall risk No threat association improved risk of eR- BC increased threat enhanced risk No danger association elevated threat No threat association enhanced threat No threat association improved threat No threat association increased threat No danger association Decreased threat No threat association enhanced all round risk No threat association No risk association elevated all round threat No risk association Decreased threat of eR+ BC improved threat of eR- BC No risk association Decreased threat No threat association improved danger of eR+ No risk association No risk association Decreased danger of eR- BC Decreased risk of eR+ BC No danger association Decreased risk of eR+ No danger association No threat association increased all round threat Decreased all round risk No threat association No danger association increased risk of eR- BC elevated danger improved threat enhanced danger elevated danger in eR+ earlier age of onset increased danger (A allele) earlier age of onset (C allele) Decreased risk Decreased danger increased risk Decreased survival Reference 150 142 38 33 33 33 36 151 152 32 147 153 31 141 33 33 33 33 141 33 33 33 33 33 33 33 142 srep39151 43 154 155 156 jir.2014.0227 157 158 159MIR455 MIR487 MIR495 MIRrs2060133 C/G rs1951032 G/A rs2281611 C/A rs3746444 A/Grs3746444 T/CMIR513A-2 MIR544 MIR548A-2 MIR595 MIR605 MIR606 MIR608 MIRrs2018562 A/G rs10144193 A/T rs878175 A/G rs4909238 A/G rs2043556 *A rs12266981 G/A rs4919510 C/G rs8041885 A/G rs8041044 C/AMIR659 MIRrs5750504 T/A rs12586258 G/A rs7141987 A/GATF1 three UTR BMPR1B three UTR BRCA1 3 UTR HPGD 3 UTR IGF-1R 3 UTR IL23R 3 UTRrs11169571 C/T rs1434536 C/T rs799917 C/T rs8752 G/A rs28674628 A/G rs10889677 A/CmiR320 MRe miR125b MRe miR638 MRe miR4855p MRe miR5155p MRe let7 MReIQGAP1 3 UTR ITGB4 three UTRrs1042538 A/T rs743554 A/GmiR124 MRe miR34a MRepredictedChinese Swedish(Continued)submit your manuscript | www.dovepress.comBreast Cancer: Targets and Therapy 2015:DovepressDovepressmicroRNAs in breast cancerTable two (Continued)miRNA locus KRAS three UTR SNP rs61764370 T/G Comments let7 MRe Population Caucasian Clinical observation elevated frequency in BRCA1 carriers/no threat association improved risk of TNBC Decreased risk increased threat and poor survival earlier age of onset elevated risk improved risk Decreased risk Decreased overall danger No risk association Decreased risk of eR+ BC No risk association increas.A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy 2015:submit your manuscript | www.dovepress.comDovepressGraveel et alDovepressTable 2 (Continued)Gene locus MIR423 SNP rs6505162 A/C Comments premiRNA Population Caucasian Jewish BRCA2 carriers Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans Chinese Asians Caucasians Asians Caucasians Chinese Caucasians Asians Caucasians Asians Caucasians Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Jewish BRCA2 carriers Caucasian italian Chinese Jewish BRCA1 carriers Chinese Clinical observation Lowered danger Later age of onset No threat association No risk association No danger association Decreased threat of eR+ BC No threat association improved overall danger No danger association elevated danger of eR- BC increased risk increased threat No risk association increased danger No danger association elevated risk No threat association increased threat No danger association elevated risk No threat association Decreased risk No danger association improved all round risk No danger association No risk association enhanced general threat No threat association Decreased danger of eR+ BC increased danger of eR- BC No risk association Decreased risk No threat association increased danger of eR+ No danger association No threat association Decreased danger of eR- BC Decreased risk of eR+ BC No danger association Decreased threat of eR+ No threat association No threat association enhanced overall danger Decreased all round threat No threat association No danger association elevated threat of eR- BC enhanced danger enhanced risk increased threat improved threat in eR+ earlier age of onset improved threat (A allele) earlier age of onset (C allele) Decreased threat Decreased risk elevated danger Reduced survival Reference 150 142 38 33 33 33 36 151 152 32 147 153 31 141 33 33 33 33 141 33 33 33 33 33 33 33 142 srep39151 43 154 155 156 jir.2014.0227 157 158 159MIR455 MIR487 MIR495 MIRrs2060133 C/G rs1951032 G/A rs2281611 C/A rs3746444 A/Grs3746444 T/CMIR513A-2 MIR544 MIR548A-2 MIR595 MIR605 MIR606 MIR608 MIRrs2018562 A/G rs10144193 A/T rs878175 A/G rs4909238 A/G rs2043556 *A rs12266981 G/A rs4919510 C/G rs8041885 A/G rs8041044 C/AMIR659 MIRrs5750504 T/A rs12586258 G/A rs7141987 A/GATF1 3 UTR BMPR1B 3 UTR BRCA1 three UTR HPGD three UTR IGF-1R three UTR IL23R three UTRrs11169571 C/T rs1434536 C/T rs799917 C/T rs8752 G/A rs28674628 A/G rs10889677 A/CmiR320 MRe miR125b MRe miR638 MRe miR4855p MRe miR5155p MRe let7 MReIQGAP1 3 UTR ITGB4 3 UTRrs1042538 A/T rs743554 A/GmiR124 MRe miR34a MRepredictedChinese Swedish(Continued)submit your manuscript | www.dovepress.comBreast Cancer: Targets and Therapy 2015:DovepressDovepressmicroRNAs in breast cancerTable 2 (Continued)miRNA locus KRAS three UTR SNP rs61764370 T/G Comments let7 MRe Population Caucasian Clinical observation improved frequency in BRCA1 carriers/no danger association increased danger of TNBC Decreased threat enhanced threat and poor survival earlier age of onset improved threat elevated risk Decreased threat Decreased all round risk No threat association Decreased risk of eR+ BC No threat association increas.
